POMDOCTOR LIMITED Successfully Meets Nasdaq's Bid Price Norms After Adversity

POMDOCTOR LIMITED: A New Dawn of Compliance

GUANGZHOU, China, November 6, 2026 — In a significant development, POMDOCTOR LIMITED (NASDAQ: POM), a progressive digital healthcare firm, announced its successful compliance with Nasdaq's bid price requirements. This milestone was marked by receiving a compliance letter from Nasdaq on November 5, 2026, affirming that the company's stock price has regained the necessary minimum bid price of $1.00 per share, as outlined in Rule 5450(a)(1).

The rejoicing comes after a challenging period for Pomdoctor, which had been under scrutiny following a notice issued on October 6, 2026, indicating the company’s stock price had dipped below the $1.00 threshold for 30 consecutive trading days. Initially, a hearing was set for November 12, 2026, regarding the potential delisting of its shares. However, due to the recent compliance confirmation, this hearing has been canceled, allowing shared trading to continue under the ticker symbol "POM".

POMDOCTOR’s resilience reflects its commitment to its vision of enhancing healthcare through innovative technology. As an entity specializing in AI-enabled healthcare solutions, POMDOCTOR is at the forefront of revolutionizing the way healthcare services are delivered. The company strives to harness the power of artificial intelligence, wearable tech, healthcare payment networks, and real-world healthcare data, all to offer a more personalized and data-driven approach to medical care.

“The journey towards compliance is a testimony to our dedication and adaptability in a fast-paced industry. Our resources and innovations empower healthcare providers, and we are excited about the future,” commented a spokesperson from POMDOCTOR. The company aims not only to advance healthcare services but also to improve healthcare outcomes holistically for its stakeholders, which include patients, healthcare providers, and various ecosystem participants.

In pursuing these aspirations, POMDOCTOR is continuously developing a robust predictive healthcare data infrastructure. This initiative is intended to close the gaps in current healthcare services, providing a framework that supports long-term value creation for all participants involved.

The company's advanced capabilities enable it to stay ahead of trends, ensuring that it remains relevant in this dynamic market landscape. As healthcare continues to evolve due to technological advancements, POMDOCTOR is strategically positioned to meet emerging demands and overcome challenges, setting a standard for excellence in digital healthcare.

Investors and market watchers are encouraged to remain engaged, as POMDOCTOR's forward-looking strategies are aimed at expanding its footprint in the industry. While the company emphasizes its growth potential and innovative solutions, it also acknowledges that future results may deviate from current expectations due to various known and unknown factors affecting the market.

To learn more about POMDOCTOR LIMITED and its cutting-edge healthcare solutions, visit their official website at ir.7shiliu.com. This compliance success story is just one chapter in POMDOCTOR’s ongoing narrative of impactful healthcare innovation.

About POMDOCTOR LIMITED
POMDOCTOR LIMITED (NASDAQ: POM) is dedicated to revolutionizing healthcare through technology. The company integrates state-of-the-art AI solutions to enhance diagnostic accuracy and track patient progress, thereby pushing the boundaries of traditional healthcare practices. By prioritizing predictive capabilities, POMDOCTOR is set to transform patient outcomes and redefine the healthcare landscape in years to come.

For further details and narratives surrounding POMDOCTOR's initiatives, feel free to reach out to their investor relations team at [email protected] or contact Ascent Investor Relations at +1-646-932-7242.